Atenolol News and Research

RSS

Atenolol is a ß1 receptor specific antagonist, a drug belonging to the group of ß-blockers, a class of drugs used primarily in cardiovascular diseases. Introduced in 1976, atenolol was developed as a replacement for propranolol in the treatment of hypertension. Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, arrhythmias, angina (chest pain) and to treat and reduce the risk of heart complications following myocardial infarction (heart attack)

Sanofi-Aventis, Boehringer, World Heart Federation collaborate to raise awareness about AF

The World Heart Federation, sanofi-aventis and Boehringer Ingelheim have announced their collaboration on the AF AWARE campaign today, to raise awareness of atrial fibrillation (AF) and its links to severe consequences including cardiovascular mortality, stroke and CV hospitalizations.

16 Feb 2011

Tracking heart rate can provide important marker of health issues: Research

An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.

13 Aug 2010

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.

30 Jul 2010

Hypertension: Regular nifedipine administration may lead to development of GERD

Nifedipine, a calcium-channel blocker, was shown to decrease lower esophageal sphincter pressure and increase esophageal acid exposure time, while atenolol, a b1 blocker, was shown to inhibit relaxation of the smooth muscle of the esophagus. However, the influence of these anti-hypertensive drugs on the segment of esophageal body contraction using high-resolution manometry was not fully investigated.

5 Mar 2010

Drugs and fruit juices - a combination to avoid

It has been common knowledge for a number of years that grapefruit juice can influence the absorption of certain drugs, potentially turning normal doses into toxic overdoses.

20 Aug 2008

New reasons to avoid grapefruit juice when taking certain drugs

Scientists and consumers have known for years that grapefruit juice can increase the absorption of certain drugs - with the potential for turning normal doses into toxic overdoses.

19 Aug 2008

Significant gender differences in heart disease

Women may respond less favorably than men to cardiovascular disease (CV) drug-treatments for enlarged heart, according to NewYork-Presbyterian Hospital/Weill Cornell Medical Center physician-scientists

1 Jul 2008

High blood pressure treatment effective in reversing vascular damage

A hypertension medication called olmesartan medoxomil is effective in reversing the narrowing of the arteries that occurs in patients with high blood pressure, according to a new study.

16 Jun 2008

For hypertension patients, preventing or reducing enlarged heart may decrease risk for diabetes

High-blood-pressure patients treated for enlarged heart (left ventricular hypertrophy, LVH) who have regression or prevention of LVH may also have a better chance of preventing diabetes.

1 Nov 2007

Memory tasks require more coordinated brain blood flow for people with high blood pressure

Blood flow to the parts of the brain that support memory function differs between people with high blood pressure and those with normal blood pressure, and this difference seems to increase when high blood pressure is treated with medications, researchers reported today at the American Heart Association's 61st Annual Fall Conference of the Council for High Blood Pressure Research.

27 Sep 2007

Reducing enlarged heart decreases risk of heart failure

For high-blood-pressure patients, preventing or reducing enlarged heart (left ventricular hypertrophy or LVH) reduces risk of heart failure.

13 Sep 2007

Preventing enlarged heart reduces heart failure

For high-blood-pressure patients, preventing or reducing enlarged heart (left ventricular hypertrophy or LVH) reduces risk of heart failure. The study is published in the Sept. 4 Annals of Internal Medicine and led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

11 Sep 2007

High blood pressure medication strategy proves effective in Hispanic women

Hispanic women with hypertension and coronary artery disease respond better to drug regimens aimed at controlling high blood pressure than non-Hispanic white women, University of Florida researchers report.

13 Jul 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Tenormin

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Atenolol Tablets USP (atenolol).

12 Jul 2007

Ranbaxy granted approval to manufacture Atenolol

Ranbaxy Laboratories has announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Atenolol Tablets USP, 25 mg, 50 mg, and 100 mg.

2 Jan 2007

New tool to study protein kinase A - linked to heart failure

Scientists studying heart cells have devised a new way to visualize and quantify the rise and fall in the activity of a key enzyme linked to heart failure.

8 Aug 2006

Trandolapril and verapamil reduce risk of developing diabetes in Hispanic patients

The combination of drugs traditionally used to control blood pressure might not be ideal for Hispanic patients, University of Florida researchers warn.

23 May 2006

Diabetics benefit less from anti-hypertensive treatment to reduce enlarged heart

Standard blood-pressure-lowering treatment to reduce dangerously enlarged hearts is much less effective and less beneficial in diabetic vs. nondiabetic patients, a team led by NewYork-Presbyterian Hospital/Weill Cornell Medical Center researchers reports in this month's issue of Circulation.

20 Mar 2006

Blood pressure near the heart is more predictive of cardiovascular outcomes than blood pressure measured in the arm

Results from a new study show that amlodipine-based (calcium channel blocker) treatment is much more effective at reducing blood pressure near the heart than a conventional atenolol-based (beta blocker) regimen.

14 Nov 2005

Norvasc better than beta blockers for lowering blood pressure

According to a study presented at a meeting of the American Heart Association, Norvasc, was more effective at reducing blood pressure near the heart than standard, older treatments such as beta blockers.

14 Nov 2005